- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.11. | ABVC BioPharma GAAP EPS of -$0.02, revenue of $0.38M | 1 | Seeking Alpha | ||
| 14.11. | ABVC BioPharma, Inc. Reports Q3 2024 Financial Results and Operational Milestones | 59 | GlobeNewswire (Europe) | ABVC BioPharma Achieved its First Operational Profit, with a 102% Improvement over the Third Quarter of Last Year.Incremental Payments Received based on Executed Global Licensing Agreements that could... ► Artikel lesen | |
| 14.11. | ABVC BIOPHARMA, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.11. | ABVC BIOPHARMA, INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| ABVC BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 04.11. | ABVC BIOPHARMA, INC. - 8-K, Current Report | - | SEC Filings | ||
| 22.10. | ABVC BioPharma sichert sich zusätzliche Lizenzgebühren | 3 | Investing.com Deutsch | ||
| 22.10. | ABVC BioPharma, Inc.: ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners | 46 | GlobeNewswire (Europe) | FREMONT, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous... ► Artikel lesen | |
| 22.10. | ABVC BioPharma secures additional licensing fees | 1 | Investing.com | ||
| 19.10. | ABVC BioPharma switches to new independent accounting firm | 1 | Investing.com | ||
| 19.10. | ABVC BioPharma wechselt zu neuer unabhängiger Wirtschaftsprüfungsgesellschaft | 1 | Investing.com Deutsch | ||
| 18.10. | ABVC BIOPHARMA, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.09. | ABVC BIOPHARMA, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.08. | ABVC BioPharma GAAP EPS of -$0.09 | 1 | Seeking Alpha | ||
| 15.08. | ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements | 143 | GlobeNewswire (Europe) | • Executed Global Licensing Agreements that could provide up to $292 million in income • Received Cash Milestone Incomes of $116,000 • Achieved Significant Improvements in Earnings • Obtained... ► Artikel lesen | |
| 15.08. | ABVC BIOPHARMA, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.08. | ABVC BIOPHARMA, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 23.07. | ABVC BIOPHARMA, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.07. | ABVC BIOPHARMA, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.06. | ABVC Biopharma files to sell 1M shares of common stock for holders | 1 | Seeking Alpha | ||
| 21.06. | ABVC BIOPHARMA, INC. - S-1, General form for registration of securities | 1 | SEC Filings |
Seite:
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NANOREPRO | 1,600 | +3,90 % | NanoRepro Aktie: Alles im Blick? | Die NanoRepro AG, ein führender Entwickler medizinischer Selbsttests, zeigt sich trotz wirtschaftlicher Herausforderungen widerstandsfähig. Am 09. November 2024 notierte die Aktie bei 1,64 EUR, unverändert... ► Artikel lesen | |
| BIOXXMED | 2,900 | -3,97 % | EQS-Adhoc: bioXXmed AG: Platzierung der Kapitalerhöhung abgeschlossen | EQS-Ad-hoc: bioXXmed AG / Schlagwort(e): Sonstiges
bioXXmed AG: Platzierung der Kapitalerhöhung abgeschlossen
01.10.2024 / 17:12 CET/CEST
Veröffentlichung einer Insiderinformation nach Artikel... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,046 | -2,13 % | Sirona Biochem meldet Veröffentlichung einer bahnbrechenden Studie zu Wirkstoff TFC-1326 im Journal of Cosmetic Dermatology | Vancouver, Kanada - 20. November 2024 / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB: ZSB) ist
stolz, die Veröffentlichung eines wichtigen Forschungsartikels im renommierten Journal of... ► Artikel lesen | |
| TREVENA | 0,153 | 0,00 % | Trevena Inc.: Trevena Reports Third Quarter 2024 Results and Provides Business Update | CHESTERBROOK, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with... ► Artikel lesen | |
| REDHILL BIOPHARMA | 6,370 | -6,32 % | RedHill Biopharma Ltd.: New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality | Data, from a post hoc analysis of the randomized, placebo-controlled, double-blind phase 2/3 study of oral opaganib in COVID-19 pneumonia, showing a 62% reduction in mortality and a 21% improvement... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 0,530 | -4,64 % | BioXcel Therapeutics-Aktie erreicht 52-Wochen-Tief bei 0,50 US-Dollar | ||
| CELLECTIS | 1,718 | -1,83 % | Cellectis Provides Business Updates and Financial Results for Third Quarter 2024 | UCART22 and UCART20x22: enrollment ongoing, Phase 1 dataset and late-stage development strategy to be presented in 2025AstraZeneca partnership: R&D activities are ongoing on three programs - one allogeneic... ► Artikel lesen | |
| SPERO THERAPEUTICS | 1,150 | +0,52 % | Spero Therapeutics, Inc.: Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update | Phase 3 PIVOT-PO trial of tebipenem HBr remains on track to complete enrollment in 2H 2025 Reiterate cash runway into mid-2026; Q3 2024 ending cash balance of $76.3M CAMBRIDGE, Mass., Nov.... ► Artikel lesen | |
| BIORA THERAPEUTICS | 1,640 | 0,00 % | Biora Therapeutics, Inc.: Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results | Testing in advanced animal model planned in Q4 for smaller, 00-size BioJet device with largest capacity of any ingestible injectable Company granted extension until December 9 to regain compliance... ► Artikel lesen | |
| ALTERITY THERAPEUTICS | 0,001 | 0,00 % | ALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary | ||
| ADICET BIO | 0,957 | +3,63 % | Adicet Bio startet Studie für innovative Krebstherapie | ||
| DURECT | 0,835 | -1,76 % | DURECT Corporation Reports Third Quarter 2024 Financial Results and Provides Business Update | - Seeking to initiate Phase 3 registrational trial for larsucosterol with topline results expected within two years of initiation
- Webcast of Earnings Call... ► Artikel lesen | |
| ALTAMIRA THERAPEUTICS | 0,430 | 0,00 % | Altamira Therapeutics Ltd: Altamira Therapeutics Provides Update on Nasdaq Listing | Hamilton, Bermuda, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq:CYTO) today announced that it received on September 30, 2024, a letter from the... ► Artikel lesen | |
| SERES THERAPEUTICS | 0,772 | +1,50 % | Seres Therapeutics: Chefjurist verkauft Aktien im Wert von 474 US-Dollar | ||
| WINDTREE THERAPEUTICS | 0,510 | 0,00 % | WINDTREE THERAPEUTICS INC /DE/ - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB |
Das Unternehmen ABVC BIOPHARMA INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,550 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ABVC BIOPHARMA INC finden Sie auf Wallstreet Online.
